Fierce Biotech
Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss
Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and concern,” Kolon TissueGene is laying off 37 employees at its Maryland headquarters. | Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and…
